explore -WSS

explore

author：Wikipedia 2025-09-28 20:05:19 Page View：6

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

A California biotech developing a combination therapy with the obesity drug Zepbound has raised a $170 million Series D round.

The company, BioAge, raised money from more than a dozen investors. Sofinnova Investments led the round, which also included Eli Lilly and Amgen’s venture arms and previous investor Andreessen Horowitz.

BioAge’s primary focus is in developing medications that boost a person’s healthspan, or the number of healthy years a person lives. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound. That drug program is what grabbed Sofinnova’s attention, according to managing partner Jim Healy, who recently became chairman of BioAge’s board.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： A look at other Americans who have crossed into North Korea over the years
Next article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Wikipedia

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

Aspartame and sugar

AdobeTheInternationalAgencyforResearchonCancer(IARC,anentitywithintheWorldHealthOrganization)recentl

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

FILE-RichardMoore,theChiefofBritain'sSecretIntelligenceService,alsoknownasMI6,answersquestionsafterg